English

PHIO PHARMACEUTICALS CORP.

EDGAR

PHIO Current report (8-K) · filed 2026-10-13

101 filing records in this dataset, filed from 2011-10-25 to 2026-10-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2020 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-2.62 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -8802000 USD Source
Operating Cash Flow: -6179000 USD Source

Free cash flow

-2.62 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -8802000 USD Source
Operating Cash Flow: -6179000 USD Source
Capital Expenditure: 19000 USD Source
Capital Expenditure: 18000 USD Source

Cash and cash equivalents: 13 million USD 2026-06-30 Source
Exact value

12996000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 11.6 million shares 2026-06-30 Source
Exact value

11617250 shares

Reported share-count change

142.12% · 6.82 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

4798154 shares · 2025-06-30· Source
11617250 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2020-01-01 – 2020-12-31

Exact inputs and evidence

Revenue: 0 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 0 USD · 2020-04-01 – 2020-06-30 Source
Revenue: 0 USD · 2020-07-01 – 2020-09-30 Source
Revenue: 0 USD · 2020-01-01 – 2020-12-31 Source
Revenue: 0 USD · 2020-01-01 – 2020-09-30 Source

Net income

-12.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -2392000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -8698000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -6327000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -4003000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -4138000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-12.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -5900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -3815000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -7979000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -5900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -4003000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -8038000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -4003000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

7 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 12000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 12000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 12000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: -0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: -0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: -0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-12.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -5900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -3815000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -7979000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -5900000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -4003000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -8038000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -4003000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 12000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 12000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 12000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: -0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: -0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: -0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2020-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 1.55 million

Prior period

−USD 7.15 million

2024-01-01 – 2024-12-31
Current period

−USD 8.7 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-8698000 − -7150000 = -1548000 USD

-7150000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-8698000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Year-over-year change in Net income: -1548000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -8698000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#558036 Filing: 000143774926007078 Input fundies:NetIncome: -7150000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#529720 Filing: 000143774926007078
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 867,000

Prior period

−USD 7.11 million

2024-01-01 – 2024-12-31
Current period

−USD 7.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-7979000 − -7112000 = -867000 USD

-7112000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-7979000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Year-over-year change in Operating cash flow: -867000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -7979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#587528 Filing: 000143774926007078 Input fundies:OperatingCashFlow: -7112000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#588227 Filing: 000143774926007078
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+1,100%

Prior period

USD 1,000

2024-01-01 – 2024-12-31
Current period

USD 12,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

12000 − 1000 = 11000 USD

1000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
12000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Year-over-year change in Capital expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 12000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#590386 Filing: 000143774926007078 Input fundies:CapitalExpenditure: 1000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#591073 Filing: 000143774926007078
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 0
Operating costs Derived USD 8.79 million
Operating income −USD 8.79 million
Tax, interest and other Derived USD 1,000
Net income −USD 8.79 million

Cash

Operating cash flow −USD 8.8 million
Capital expenditure USD 19,000
Free cash flow Derived −USD 8.82 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 47,547% of revenue.
2017 Operating loss: operating costs were 93,847% of revenue.
2018 Operating loss: operating costs were 5,436% of revenue.
2019 Operating loss: operating costs were 42,895% of revenue.
2020 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	19000	9034000 Derived	-9015000	-21000 Derived	-8994000	-7764000 Derived	Source 2016-01-01 – 2016-12-31: 19000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -9015000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -8994000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -7760000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 4000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	15000	14077000 Derived	-14062000	-1610000 Derived	-12452000	-9717000 Derived	Source 2017-01-01 – 2017-12-31: 15000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -14062000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -12452000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -9514000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 203000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	138000	7502000 Derived	-7364000	-4000 Derived	-7360000	-7525000 Derived	Source 2018-01-01 – 2018-12-31: 138000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -7364000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -7360000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -7520000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 5000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	21000	9008000 Derived	-8987000	-79000 Derived	-8908000	-8717000 Derived	Source 2019-01-01 – 2019-12-31: 21000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -8987000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -8908000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -8645000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 72000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	8793000 Derived	-8793000	1000 Derived	-8794000	-8821000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -8793000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -8794000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -8802000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 19000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	34000	Revenue: 34000 Open source
20162016-12-31	Revenue	19000	Revenue: 19000 Open source
20172017-12-31	Revenue	15000	Revenue: 15000 Open source
20182018-12-31	Revenue	138000	Revenue: 138000 Open source
20192019-12-31	Revenue	21000	Revenue: 21000 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 34000 Open source
20162016-12-31	Year over year	-44.1%	Revenue: 19000 Open source Revenue: 34000 Open source
20172017-12-31	Year over year	-21.1%	Revenue: 15000 Open source Revenue: 19000 Open source
20182018-12-31	Year over year	820%	Revenue: 138000 Open source Revenue: 15000 Open source
20192019-12-31	Year over year	-84.8%	Revenue: 21000 Open source Revenue: 138000 Open source
20202020-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 21000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -42,795.2% 2019

Net margin -42,419% 2019

Free cash flow margin -41,509.5% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-30,108.8%	Operating Income: -10237000 Open source Revenue: 34000 Open source
20162016-12-31	Operating margin	-47,447.4%	Operating Income: -9015000 Open source Revenue: 19000 Open source
20172017-12-31	Operating margin	-93,746.7%	Operating Income: -14062000 Open source Revenue: 15000 Open source
20182018-12-31	Operating margin	-5,336.2%	Operating Income: -7364000 Open source Revenue: 138000 Open source
20192019-12-31	Operating margin	-42,795.2%	Operating Income: -8987000 Open source Revenue: 21000 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -8793000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	-30,067.6%	Net Income: -10223000 Open source Revenue: 34000 Open source
20162016-12-31	Net margin	-47,336.8%	Net Income: -8994000 Open source Revenue: 19000 Open source
20172017-12-31	Net margin	-83,013.3%	Net Income: -12452000 Open source Revenue: 15000 Open source
20182018-12-31	Net margin	-5,333.3%	Net Income: -7360000 Open source Revenue: 138000 Open source
20192019-12-31	Net margin	-42,419%	Net Income: -8908000 Open source Revenue: 21000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -8794000 Open source Revenue: 0 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 34000 Open source
20162016-12-31	Free cash flow margin	-40,863.2%	Revenue: 19000 Open source Operating Cash Flow: -7760000 Open source Capital Expenditure: 4000 Open source
20172017-12-31	Free cash flow margin	-64,780%	Revenue: 15000 Open source Operating Cash Flow: -9514000 Open source Capital Expenditure: 203000 Open source
20182018-12-31	Free cash flow margin	-5,452.9%	Revenue: 138000 Open source Operating Cash Flow: -7520000 Open source Capital Expenditure: 5000 Open source
20192019-12-31	Free cash flow margin	-41,509.5%	Revenue: 21000 Open source Operating Cash Flow: -8645000 Open source Capital Expenditure: 72000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -8802000 Open source Capital Expenditure: 19000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -8.8M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-7760000	Operating Cash Flow: -7760000 Open source
20172017-12-31	Operating cash flow	-9514000	Operating Cash Flow: -9514000 Open source
20182018-12-31	Operating cash flow	-7520000	Operating Cash Flow: -7520000 Open source
20192019-12-31	Operating cash flow	-8645000	Operating Cash Flow: -8645000 Open source
20202020-12-31	Operating cash flow	-8802000	Operating Cash Flow: -8802000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -8.8M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-7764000	Operating Cash Flow: -7760000 Open source Capital Expenditure: 4000 Open source
20172017-12-31	Free cash flow	-9717000	Operating Cash Flow: -9514000 Open source Capital Expenditure: 203000 Open source
20182018-12-31	Free cash flow	-7525000	Operating Cash Flow: -7520000 Open source Capital Expenditure: 5000 Open source
20192019-12-31	Free cash flow	-8717000	Operating Cash Flow: -8645000 Open source Capital Expenditure: 72000 Open source
20202020-12-31	Free cash flow	-8821000	Operating Cash Flow: -8802000 Open source Capital Expenditure: 19000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

17.3% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2015-12-31	Liabilities / assets	Not reported	Total Assets: 11159000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 13397000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 4098000 Open source
20182018-12-31	Liabilities / assets	11.4%	Total Liabilities: 1744000 Open source Total Assets: 15322000 Open source
20192019-12-31	Liabilities / assets	28.5%	Total Liabilities: 2291000 Open source Total Assets: 8039000 Open source
20202020-12-31	Liabilities / assets	17.3%	Total Liabilities: 2722000 Open source Total Assets: 15739000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.91× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	4.84×	Current Assets: 10978000 Open source Current Liabilities: 2269000 Open source
20162016-12-31	Current assets / current liabilities	5.16×	Current Assets: 13106000 Open source Current Liabilities: 2542000 Open source
20172017-12-31	Current assets / current liabilities	1.69×	Current Assets: 3832000 Open source Current Liabilities: 2265000 Open source
20182018-12-31	Current assets / current liabilities	8.69×	Current Assets: 15150000 Open source Current Liabilities: 1744000 Open source
20192019-12-31	Current assets / current liabilities	3.88×	Current Assets: 7300000 Open source Current Liabilities: 1880000 Open source
20202020-12-31	Current assets / current liabilities	6.91×	Current Assets: 15164000 Open source Current Liabilities: 2196000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 8.99 million Exact value Exact value: -8994000 USD 2016-01-01 – 2016-12-31: -8994000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2016-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -8994000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8994000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000119312518096053/rxii-20171231.xml#390967 Filing: 000119312518096053 The citation records this snapshot. The page link may show a newer release later.	−USD 7.76 million Exact value Exact value: -7760000 USD 2016-01-01 – 2016-12-31: -7760000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2016-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -7760000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7760000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000119312518096053/rxii-20171231.xml#389856 Filing: 000119312518096053 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2016-01-01 – 2016-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2016-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000119312518096053/rxii-20171231.xml#391868 Filing: 000119312518096053 The citation records this snapshot. The page link may show a newer release later.	−USD 7.76 million Calculation and evidence -7760000 − 4000 USD Exact free cash flow: -7764000 USD 2016-01-01 – 2016-12-31: -7760000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2016-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -7764000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7760000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000119312518096053/rxii-20171231.xml#389856 Filing: 000119312518096053 Input fundies:CapitalExpenditure: 4000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000119312518096053/rxii-20171231.xml#391868 Filing: 000119312518096053 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 12.45 million Exact value Exact value: -12452000 USD 2017-01-01 – 2017-12-31: -12452000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2017-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -12452000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12452000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316819000795/phio-20181231.xml#97525 Filing: 000168316819000795 The citation records this snapshot. The page link may show a newer release later.	−USD 9.51 million Exact value Exact value: -9514000 USD 2017-01-01 – 2017-12-31: -9514000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2017-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -9514000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9514000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316819000795/phio-20181231.xml#226897 Filing: 000168316819000795 The citation records this snapshot. The page link may show a newer release later.	USD 203,000 Exact value Exact value: 203000 USD 2017-01-01 – 2017-12-31: 203000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2017-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 203000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 203000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316819000795/phio-20181231.xml#228584 Filing: 000168316819000795 The citation records this snapshot. The page link may show a newer release later.	−USD 9.72 million Calculation and evidence -9514000 − 203000 USD Exact free cash flow: -9717000 USD 2017-01-01 – 2017-12-31: -9514000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 203000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2017-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -9717000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9514000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316819000795/phio-20181231.xml#226897 Filing: 000168316819000795 Input fundies:CapitalExpenditure: 203000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316819000795/phio-20181231.xml#228584 Filing: 000168316819000795 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 7.36 million Exact value Exact value: -7360000 USD 2018-01-01 – 2018-12-31: -7360000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2018-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -7360000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7360000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316820000969/phio-20191231.xml#122627 Filing: 000168316820000969 The citation records this snapshot. The page link may show a newer release later.	−USD 7.52 million Exact value Exact value: -7520000 USD 2018-01-01 – 2018-12-31: -7520000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2018-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -7520000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7520000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316820000969/phio-20191231.xml#144424 Filing: 000168316820000969 The citation records this snapshot. The page link may show a newer release later.	USD 5,000 Exact value Exact value: 5000 USD 2018-01-01 – 2018-12-31: 5000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2018-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 5000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316820000969/phio-20191231.xml#144796 Filing: 000168316820000969 The citation records this snapshot. The page link may show a newer release later.	−USD 7.53 million Calculation and evidence -7520000 − 5000 USD Exact free cash flow: -7525000 USD 2018-01-01 – 2018-12-31: -7520000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 5000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2018-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -7525000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7520000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316820000969/phio-20191231.xml#144424 Filing: 000168316820000969 Input fundies:CapitalExpenditure: 5000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316820000969/phio-20191231.xml#144796 Filing: 000168316820000969 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 8.91 million Exact value Exact value: -8908000 USD 2019-01-01 – 2019-12-31: -8908000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2019-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -8908000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8908000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/phio-20201231.xml#152670 Filing: 000168316821001062 The citation records this snapshot. The page link may show a newer release later.	−USD 8.65 million Exact value Exact value: -8645000 USD 2019-01-01 – 2019-12-31: -8645000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2019-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -8645000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8645000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/phio-20201231.xml#158464 Filing: 000168316821001062 The citation records this snapshot. The page link may show a newer release later.	USD 72,000 Exact value Exact value: 72000 USD 2019-01-01 – 2019-12-31: 72000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2019-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 72000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 72000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/phio-20201231.xml#158098 Filing: 000168316821001062 The citation records this snapshot. The page link may show a newer release later.	−USD 8.72 million Calculation and evidence -8645000 − 72000 USD Exact free cash flow: -8717000 USD 2019-01-01 – 2019-12-31: -8645000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 72000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2019-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -8717000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8645000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/phio-20201231.xml#158464 Filing: 000168316821001062 Input fundies:CapitalExpenditure: 72000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316821001062/phio-20201231.xml#158098 Filing: 000168316821001062 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 8.79 million Exact value Exact value: -8794000 USD 2020-01-01 – 2020-12-31: -8794000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2020-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -8794000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8794000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316822001833/phio_i10k-123121.htm#582430 Filing: 000168316822001833 The citation records this snapshot. The page link may show a newer release later.	−USD 8.8 million Exact value Exact value: -8802000 USD 2020-01-01 – 2020-12-31: -8802000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2020-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -8802000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316822001833/phio_i10k-123121.htm#592198 Filing: 000168316822001833 The citation records this snapshot. The page link may show a newer release later.	USD 19,000 Exact value Exact value: 19000 USD 2020-01-01 – 2020-12-31: 19000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2020-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 19000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316822001833/phio_i10k-123121.htm#593909 Filing: 000168316822001833 The citation records this snapshot. The page link may show a newer release later.	−USD 8.82 million Calculation and evidence -8802000 − 19000 USD Exact free cash flow: -8821000 USD 2020-01-01 – 2020-12-31: -8802000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 19000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2020-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -8821000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316822001833/phio_i10k-123121.htm#592198 Filing: 000168316822001833 Input fundies:CapitalExpenditure: 19000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316822001833/phio_i10k-123121.htm#593909 Filing: 000168316822001833 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 13.29 million Exact value Exact value: -13287000 USD 2021-01-01 – 2021-12-31: -13287000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2021-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -13287000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13287000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001678/phio_i10k-123122.htm#545717 Filing: 000168316823001678 The citation records this snapshot. The page link may show a newer release later.	−USD 11.86 million Exact value Exact value: -11858000 USD 2021-01-01 – 2021-12-31: -11858000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2021-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -11858000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11858000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001678/phio_i10k-123122.htm#555325 Filing: 000168316823001678 The citation records this snapshot. The page link may show a newer release later.	USD 51,000 Exact value Exact value: 51000 USD 2021-01-01 – 2021-12-31: 51000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2021-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 51000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001678/phio_i10k-123122.htm#557018 Filing: 000168316823001678 The citation records this snapshot. The page link may show a newer release later.	−USD 11.91 million Calculation and evidence -11858000 − 51000 USD Exact free cash flow: -11909000 USD 2021-01-01 – 2021-12-31: -11858000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 51000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2021-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -11909000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11858000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001678/phio_i10k-123122.htm#555325 Filing: 000168316823001678 Input fundies:CapitalExpenditure: 51000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001678/phio_i10k-123122.htm#557018 Filing: 000168316823001678 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 11.48 million Exact value Exact value: -11480000 USD 2022-01-01 – 2022-12-31: -11480000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2022-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -11480000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11480000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002021/phio_i10k-123123.htm#482972 Filing: 000168316824002021 The citation records this snapshot. The page link may show a newer release later.	−USD 12.13 million Exact value Exact value: -12129000 USD 2022-01-01 – 2022-12-31: -12129000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2022-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -12129000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12129000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002021/phio_i10k-123123.htm#493129 Filing: 000168316824002021 The citation records this snapshot. The page link may show a newer release later.	USD 121,000 Exact value Exact value: 121000 USD 2022-01-01 – 2022-12-31: 121000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2022-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 121000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 121000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002021/phio_i10k-123123.htm#494895 Filing: 000168316824002021 The citation records this snapshot. The page link may show a newer release later.	−USD 12.25 million Calculation and evidence -12129000 − 121000 USD Exact free cash flow: -12250000 USD 2022-01-01 – 2022-12-31: -12129000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 121000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2022-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -12250000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12129000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002021/phio_i10k-123123.htm#493129 Filing: 000168316824002021 Input fundies:CapitalExpenditure: 121000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002021/phio_i10k-123123.htm#494895 Filing: 000168316824002021 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 10.83 million Exact value Exact value: -10826000 USD 2023-01-01 – 2023-12-31: -10826000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2023-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -10826000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10826000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002134/phio_i10k-123124.htm#537721 Filing: 000168316825002134 The citation records this snapshot. The page link may show a newer release later.	−USD 10.75 million Exact value Exact value: -10749000 USD 2023-01-01 – 2023-12-31: -10749000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2023-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -10749000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10749000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002134/phio_i10k-123124.htm#548573 Filing: 000168316825002134 The citation records this snapshot. The page link may show a newer release later.	USD 5,000 Exact value Exact value: 5000 USD 2023-01-01 – 2023-12-31: 5000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2023-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 5000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002134/phio_i10k-123124.htm#550089 Filing: 000168316825002134 The citation records this snapshot. The page link may show a newer release later.	−USD 10.75 million Calculation and evidence -10749000 − 5000 USD Exact free cash flow: -10754000 USD 2023-01-01 – 2023-12-31: -10749000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 5000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2023-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -10754000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10749000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002134/phio_i10k-123124.htm#548573 Filing: 000168316825002134 Input fundies:CapitalExpenditure: 5000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002134/phio_i10k-123124.htm#550089 Filing: 000168316825002134 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 7.15 million Exact value Exact value: -7150000 USD 2024-01-01 – 2024-12-31: -7150000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2024-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -7150000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7150000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#529720 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.	−USD 7.11 million Exact value Exact value: -7112000 USD 2024-01-01 – 2024-12-31: -7112000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2024-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -7112000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7112000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#588227 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.	USD 1,000 Exact value Exact value: 1000 USD 2024-01-01 – 2024-12-31: 1000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2024-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 1000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#591073 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.	−USD 7.11 million Calculation and evidence -7112000 − 1000 USD Exact free cash flow: -7113000 USD 2024-01-01 – 2024-12-31: -7112000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2024-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -7113000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7112000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#588227 Filing: 000143774926007078 Input fundies:CapitalExpenditure: 1000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#591073 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 8.7 million Exact value Exact value: -8698000 USD 2025-01-01 – 2025-12-31: -8698000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Net Income: -8698000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8698000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#558036 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.	−USD 7.98 million Exact value Exact value: -7979000 USD 2025-01-01 – 2025-12-31: -7979000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Operating Cash Flow: -7979000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#587528 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2025-01-01 – 2025-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#590386 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.	−USD 7.99 million Calculation and evidence -7979000 − 12000 USD Exact free cash flow: -7991000 USD 2025-01-01 – 2025-12-31: -7979000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PHIO PHARMACEUTICALS CORP. · 2025-12-31 PHIO PHARMACEUTICALS CORP. (edgar:1533040) Free cash flow: -7991000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:46:45Z Snapshot: e5a12cf939ea912537a59d1d2f491702bf1de10be537aee05000588ed162052a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1533040?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#587528 Filing: 000143774926007078 Input fundies:CapitalExpenditure: 12000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1533040/000143774926007078/phio20251231_10k.htm#590386 Filing: 000143774926007078 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

101 filings · 3,044 latest values · 3,044 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001533040, 1533040, PHIO, RXII, edgar:1533040

Also known as PHIO PHARMACEUTICALS CORP., Phio Pharmaceuticals Corp, Phio Pharmaceuticals Corp., RXI PHARMACEUTICALS CORP, RXi Pharmaceuticals Corp

PHIO PHARMACEUTICALS CORP.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation